Why has IL-6 emerged as an important target for treating RA and through what mechanisms does inhibition of IL-6 affect the pathogenesis of RA?
When are you inclined to use combination therapy with a DMARD and biologic, and when is monotherapy with a DMARD alone a reasonable strategy?
In patients at risk for or a previous history of serious infection, are there some biologic agents that seem to lower the risk of such a complication?
How do you initiate DMARD therapy and what agents or combinations do you employ?
How do you identify high risk patients who are likely to benefit from biological therapy?
What are the pivotal mechanisms by which IL-6 contributes to the pathogenesis of RA?
What do clinical trials tell us about what strategies are optimal for RA patients who are inadequate responders to DMARDs and/or biologic therapy?
What do current ACR guidelines recommend as far as sequencing therapy in patients who have had an insufficient response to methotrexate?
What biomarkers and clinical findings are most useful for guiding therapy in RA?
What is the evidence for early, aggressive therapy with biologics in RA?
What is the current status of B-cell targeting agents?
What are the unmet biomarker and/or therapeutic needs in patients with RA?